NeuroPace (NPCE) News Today $11.00 -0.18 (-1.61%) Closing price 03/7/2025 04:00 PM EasternExtended Trading$11.00 0.00 (0.00%) As of 03/7/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Cantor Fitzgerald Predicts Stronger Earnings for NeuroPaceMarch 9 at 2:09 AM | americanbankingnews.comCantor Fitzgerald Predicts Higher Earnings for NeuroPaceNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of NeuroPace in a report issued on Wednesday, March 5th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.54) for the year, up fromMarch 8 at 7:33 AM | marketbeat.comNeuroPace (NASDAQ:NPCE) Price Target Raised to $20.00March 8 at 4:17 AM | americanbankingnews.comNeuroPace (NASDAQ:NPCE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst SaysCantor Fitzgerald lifted their target price on NeuroPace from $19.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday.March 6, 2025 | marketbeat.comNeuroPace (NASDAQ:NPCE) Issues Earnings Results, Beats Expectations By $0.07 EPSNeuroPace (NASDAQ:NPCE - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.March 5, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | insidermonkey.comNeuroPace reports Q4 EPS (18c), consensus (22c)March 4, 2025 | markets.businessinsider.comNeuroPace sees FY25 revenue $92M-$96M, consensus $92.96MMarch 4, 2025 | markets.businessinsider.comNeuroPace, Inc. (NPCE) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comNeuroPace Inc.: Q4 Earnings SnapshotMarch 4, 2025 | finance.yahoo.comNeuroPace Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 4, 2025 | globenewswire.comUPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comNeuroPace to Present at the Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comLake Street Reaffirms Their Buy Rating on NeuroPace (NPCE)March 3, 2025 | markets.businessinsider.comNeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 78,334 SharesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) insider Martha Morrell sold 78,334 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the transaction, the insider now directly owns 81,993 shares in the company, valued at approximately $1,124,943.96. The trade was a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.February 26, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Insider Sells $1,074,742.48 in StockFebruary 26, 2025 | insidertrades.comNeuroPace (NPCE) Expected to Announce Earnings on TuesdayNeuroPace (NASDAQ:NPCE) will be releasing earnings after the market closes on Tuesday, March 4. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=668151)February 25, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 5,270,845 SharesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Ltd. Kck sold 5,270,845 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.February 21, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $49,545,943.00 in StockFebruary 21, 2025 | insidertrades.comNeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.February 20, 2025 | globenewswire.comNeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025February 19, 2025 | globenewswire.comNeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesFebruary 18, 2025 | markets.businessinsider.comNeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional SharesFebruary 18, 2025 | globenewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Short Interest UpdateNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 219,400 shares, a decline of 17.8% from the January 15th total of 267,000 shares. Based on an average daily volume of 119,100 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.6% of the company's shares are sold short.February 16, 2025 | marketbeat.comNeuroPace to repurchase shares from major holderFebruary 14, 2025 | msn.comNeuroPace stock dips after pricing $65M share offeringFebruary 14, 2025 | msn.comNeuroPace announces pricing of $65M offering of common stockFebruary 14, 2025 | markets.businessinsider.comNeuroPace Announces Pricing of Public Offering of $65 Million of Common StockFebruary 14, 2025 | globenewswire.comNeuroPace plans $65 million stock offeringFebruary 13, 2025 | msn.comNeuroPace announces $65M common stock offeringFebruary 13, 2025 | markets.businessinsider.comNeuroPace Announces Proposed Public Offering of $65 Million of Common StockFebruary 13, 2025 | globenewswire.comNeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9thFebruary 3, 2025 | globenewswire.comNeuroPace FY2025 EPS Estimate Decreased by Cantor FitzgeraldNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for NeuroPace in a report issued on Wednesday, January 29th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.80) pJanuary 31, 2025 | marketbeat.comNeuroPace price target raised to $17 from $13 at Wells FargoJanuary 30, 2025 | markets.businessinsider.comWells Fargo & Company Forecasts Strong Price Appreciation for NeuroPace (NASDAQ:NPCE) StockWells Fargo & Company raised their target price on shares of NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a report on Thursday.January 30, 2025 | marketbeat.comNeuroPace, Inc.: NeuroPace Issues 2025 Financial Guidance TargetsJanuary 30, 2025 | finanznachrichten.deLeerink Partnrs Comments on NeuroPace FY2029 EarningsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for NeuroPace in a research report issued to clients and investors on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky expects that the company willJanuary 30, 2025 | marketbeat.comNeuroPace: Strategic Growth and Market Expansion Drive Positive OutlookJanuary 30, 2025 | markets.businessinsider.comNeuroPace sees FY25 revenue $92M-$96M, consensus $91.23MJanuary 29, 2025 | markets.businessinsider.comNeuroPace's SWOT analysis: epilepsy device maker's stock poised for growthJanuary 29, 2025 | msn.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells 3,200 Shares of StockJanuary 29, 2025 | insidertrades.comNeuropace chief medical officer Morrell sells $48,032 in stockJanuary 28, 2025 | msn.comNeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 3,200 SharesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) insider Martha Morrell sold 3,200 shares of the business's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the completion of the transaction, the insider now directly owns 87,062 shares in the company, valued at approximately $1,306,800.62. This trade represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.January 28, 2025 | marketbeat.comNeuroPace Issues 2025 Financial Guidance TargetsJanuary 28, 2025 | globenewswire.comLake Street Remains a Buy on NeuroPace (NPCE)January 24, 2025 | markets.businessinsider.comCantor Fitzgerald Comments on NeuroPace FY2025 EarningsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for NeuroPace in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings of ($0.79January 23, 2025 | marketbeat.comNeuroPace initiated with a Buy at UBSJanuary 22, 2025 | markets.businessinsider.comUBS Initiates Coverage of NeuroPace (NPCE) with Buy RecommendationJanuary 22, 2025 | msn.comNeuroPace (NASDAQ:NPCE) Now Covered by UBS GroupUBS Group started coverage on NeuroPace in a research report on Tuesday. They set a "buy" rating and a $17.00 price objective on the stock.January 21, 2025 | marketbeat.comUBS sees upside for NeuroPace shares with 22% CAGR and market expansion driversJanuary 21, 2025 | msn.com Remove Ads Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address NPCE Media Mentions By Week NPCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NPCE News Sentiment▼0.760.53▲Average Medical News Sentiment NPCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NPCE Articles This Week▼192▲NPCE Articles Average Week Remove Ads Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tandem Diabetes Care News Cadre News InMode News Liquidia News MiMedx Group News Establishment Labs News BioLife Solutions News Pulse Biosciences News RxSight News Paragon 28 News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NPCE) was last updated on 3/10/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
